Johnson & Johnson Could Serve As High-Yield Bond Alternative
Johnson & Johnson remains a Buy for its stability and consistent dividends, despite short-term price fluctuations and modest ...
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Johnson & Johnson (JNJ) And Encourages Investors to Reach Out
NEW YORK, NY / ACCESSWIRE / January 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf ...
J&J Stock Falls After Company Pauses Use of Heart Device
Johnson & Johnson shares are down 3% Wednesday on safety concerns that could dim sales prospects for a new heart device, ...
What To Expect From JNJ Stock In 2025?
Johnson & Johnson stock (NYSE: JNJ) lost about 7% in 2024, underperforming the broader S&P 500 index, which gained 23% for ...
Meta’s fact-checking changes put company under political microscope
Meta’s decision to eliminate its fact-checking program marks a sharp reversal for the major social media company, quickly ...
Johnson & Johnson stock underperforms Wednesday when compared to competitors
Johnson & Johnson closed $26.58 below its 52-week high ($168.85), which the company reached on September 4th.
The Victoria Advocate3d
Johnson & Johnson's Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer's Disease
Building on decades of the Company's Alzheimer's research, two differentiated investigational therapies aim to slow ...
Cautious Outlook on Johnson & Johnson Amid Currency and Legal Challenges
Wells Fargo analyst Larry Biegelsen maintained a Hold rating on Johnson & Johnson (JNJ – Research Report) yesterday and set a price target ...
US Companies Pay Over $1 Billion in Taxes to Russia Amid Ongoing Ukraine War
American firms paid Russia $1.2bn in profit taxes in 2023, according to figures shared exclusively with Newsweek.
MM&M2d
Rx Rundown: Verdiva, Johnson & Johnson, Transcarent and more
Johnson & Johnson received Priority Review of nipocalimab in generalized myasthenia gravis. GSK’s B7-H3-targeted ...
2 Dow Stocks to Buy Hand Over Fist in 2025 and 1 to Avoid
Among the Dow Jones Industrial Average's 30 components, there are two historically cheap brand-name companies, as well as a ...
Johnson & Johnson Gets FDA Priority Review of Nipocalimab in Generalized Myasthenia Gravis
Johnson & Johnson has won Food and Drug Administration priority review for its application seeking approval of nipocalimab in certain patients with generalized myasthenia gravis.